United States - English - NLM (National Library of Medicine)

university medical pharmaceuticals corp. - chloroxylenol (unii: 0f32u78v2q) (chloroxylenol - unii:0f32u78v2q) - antibacterial hand soap uses  • handwash to help decrease bacteria on the skin • recommended for repeated use

United States - English - NLM (National Library of Medicine)

university medical pharmaceuticals corp. - chloroxylenol (unii: 0f32u78v2q) (chloroxylenol - unii:0f32u78v2q) - antibacterial hand soap uses • handwash to help decrease bacteria on the skin • recommended for repeated use when using this product do not use in or near the eyes. in case of contact rinse eyes thoroughly with water. stop use and ask a doctor if irritation or rash appears & lasts keep out of reach of children. if swallowed get medical help or contact a poison control center right away.

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - paracetamol, quantity: 500 mg - tablet, uncoated - excipient ingredients: purified talc; gelatin; purified water; colloidal anhydrous silica; magnesium stearate; maize starch; sodium starch glycollate - for the temporary relief of pain associated with headache, toothache, arthritis, osteoarthritis, sore throat, period pain, rheumatic pain, neuralgia, migraine headache, colds and flu, muscular aches and pains. reduces fever.

United States - English - NLM (National Library of Medicine)

ferring pharmaceuticals inc. - progesterone (unii: 4g7ds2q64y) (progesterone - unii:4g7ds2q64y) - milprosa™ is indicated to support embryo implantation and early pregnancy (up to 10 weeks post-embryo transfer) by supplementation of corpus luteal function as part of an assisted reproductive technology (art) treatment program for infertile women up to and including 34 years of age. limitation of use efficacy in women 35 years of age and older has not been established. milprosa is contraindicated in women with: - known sensitivity to progesterone or any of the ingredients of milprosa [see description (11)] - undiagnosed vaginal bleeding - severe hepatic impairment or disease - known or suspected malignancy of the breast - active arterial or venous thromboembolism or severe thrombophlebitis, or a history of these events risk summary milprosa is indicated to support embryo implantation and early pregnancy as part of an assisted reproductive technology treatment program in vitro fertilization (ivf) with or without intracytoplasmic sperm injection (icsi) and embryo transfer for infertile women. maternal risks a

Australia - English - Department of Health (Therapeutic Goods Administration)

proudex pharmaceuticals pty ltd - propolis dry extract, quantity: 600 mg (equivalent: lead, qty 600 ng); d-alpha-tocopheryl acid succinate, quantity: 5 mg; colloidal anhydrous silica, quantity: 5 mg - capsule, hard - excipient ingredients: magnesium stearate; carob pod - antioxidant/reduce free radicals formed in the body. anti-inflammatory/relieve inflammation. helps/enhance/improve/promote immune system function helps decrease/reduce/relieve of symptoms of common colds and flu.

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - acitretin, quantity: 10 mg - capsule, hard - excipient ingredients: titanium dioxide; purified water; sodium lauryl sulfate; iron oxide red; gelatin; maltodextrin; microcrystalline cellulose; sodium ascorbate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - acitretin may be used for the treatment of:,? severe intractable psoriasis in all its forms,? severe forms of disorders of keratinisation such as,- hyperkeratosis palmaris et plantaris,- pustulosis palmaris et plantaris,- ichthyosis,- keratosis follicularis (darier's disease),- lichen planus affecting the skin or the mucosae,- pityriasis rubra pilaris

Australia - English - Department of Health (Therapeutic Goods Administration)

douglas pharmaceuticals australia pty ltd - acitretin, quantity: 25 mg - capsule, hard - excipient ingredients: titanium dioxide; microcrystalline cellulose; purified water; iron oxide red; sodium ascorbate; iron oxide yellow; gelatin; maltodextrin; sodium lauryl sulfate; propylene glycol; butan-1-ol; isopropyl alcohol; strong ammonia solution; iron oxide black; ethanol; shellac; sulfuric acid - acitretin may be used for the treatment of:,? severe intractable psoriasis in all its forms,? severe forms of disorders of keratinisation such as,- hyperkeratosis palmaris et plantaris,- pustulosis palmaris et plantaris,- ichthyosis,- keratosis follicularis (darier's disease),- lichen planus affecting the skin or the mucosae,- pityriasis rubra pilaris

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - granisetron hydrochloride -

Australia - English - Department of Health (Therapeutic Goods Administration)

aft pharmaceuticals pty ltd - remifentanil hydrochloride, quantity: 2.194 mg (equivalent: remifentanil, qty mg) - injection, powder for - excipient ingredients: hydrochloric acid; glycine - remifentanil is indicated:,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures including cardiac surgery in adults,? as an opioid adjunct for use during induction and/or maintenance of general anaesthesia during surgical procedures but not cardiac procedures in children aged 1 to 12 years,? for continuation as an analgesic into the immediate post-operative period under the close supervision of medically qualified persons trained in the use of anaesthetic drugs, during transition to longer acting analgesia following adult cardiac surgery,when endotracheal intubation and controlled ventilation are anticipated.,? for provision of analgesia and sedation in mechanically ventilated intensive care patients.